Previous 10 | Next 10 |
SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quart...
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) traded today at a new 52-week high of $36.00. This new high was reached on above average trading volume as 881,000 shares traded hands, while the average 30-day volume is approximately 65,000 shares. Rani Therapeutics Holdings Inc. (NASDAQ:RA...
SAN JOSE, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biolog...
SAN JOSE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (NASDAQ: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will participate in a fireside chat at th...
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) traded at a new 52-week high today of $34.50. Approximately 881,000 shares have changed hands today, as compared to an average 30-day volume of 57,000 shares. Over the past year, Rani Therapeutics Holdings Inc. has traded in a range of $9.24 ...
Gainers: Merus (NASDAQ:MRUS) +36%, Nutriband (OTCQB:NTRB) +16%, Skylight Health (NASDAQ:SLHG) +16%, Rani Therapeutics (NASDAQ:RANI) +12%, Jupiter Wellness (NASDAQ:JUPW) +12%. Losers: Osmotica Pharmaceuticals (NASDAQ:OSMT) -38%, Prelude Therapeutics (NAS...
There's a good chance that someone you know (if not you personally) has a fear of syringes or injections. An estimated 50 million Americans share that fear, and a 2019 article published in the Journal of Advanced Nursing showed that 20% to 30% of all people between the ages of 20 and 40 ...
SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Vi...
Gainers: FIXX +9.8%. DTIL +7.6%. REGI +5.3%. SPPI +5.2%. RANI +4.7%. Losers: EAR -51.2%. SYBX -8.9%. GRIN -6.4%. QRVO -6.4%. FA -5.0%. For further details see: FIXX, DTIL, EAR and SYBX among after hours movers
- IPO in July 2021 raised $84.3 million in gross proceeds - - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors’ appointments - SAN JOSE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Rani Therapeutics Holdings Inc. Company Name:
RANI Stock Symbol:
NASDAQ Market:
Rani Therapeutics Holdings Inc. Website:
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a...
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and Pr...
2024-05-16 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...